Difference between revisions of "Hepatoblastoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
m (Text replacement - "style="background-color:#1a9851" |Phase III" to "style="background-color:#1a9851" |Phase 3") |
||
| Line 23: | Line 23: | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | |[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | ||
|1998-2006 | |1998-2006 | ||
| − | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-de-esc) |
|[[#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]] | |[[#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]] | ||
| style="background-color:#eeee01" |Non-inferior complete resection rate | | style="background-color:#eeee01" |Non-inferior complete resection rate | ||
| Line 51: | Line 51: | ||
|[https://doi.org/10.1200/JCO.2000.18.14.2665 Ortega et al. 2000] | |[https://doi.org/10.1200/JCO.2000.18.14.2665 Ortega et al. 2000] | ||
|1989-1992 | |1989-1992 | ||
| − | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-switch-ic) |
|Cisplatin, 5-FU, Vincristine | |Cisplatin, 5-FU, Vincristine | ||
| | | | ||
| Line 65: | Line 65: | ||
|[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | |[https://www.nejm.org/doi/10.1056/NEJMoa0810613 Perilongo et al. 2009 (SIOPEL 3)] | ||
|1998-2006 | |1998-2006 | ||
| − | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|[[#Cisplatin_monotherapy|Cisplatin]] | |[[#Cisplatin_monotherapy|Cisplatin]] | ||
| style="background-color:#eeee01" |Non-inferior complete resection rate | | style="background-color:#eeee01" |Non-inferior complete resection rate | ||
| Line 95: | Line 95: | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30895-7/fulltext Katzenstein et al. 2019 (AHEP0731)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30895-7/fulltext Katzenstein et al. 2019 (AHEP0731)] | ||
|2010-2014 | |2010-2014 | ||
| − | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (E-esc) |
|[[#Observation|Observation]] | |[[#Observation|Observation]] | ||
| style="background-color:#91cf60" |Seems to have superior EFS | | style="background-color:#91cf60" |Seems to have superior EFS | ||
Revision as of 02:01, 16 December 2021
7 regimens on this page
7 variants on this page
|
All lines of therapy
Cisplatin monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Perilongo et al. 2009 (SIOPEL 3) | 1998-2006 | Phase 3 (E-de-esc) | Cisplatin & Doxorubicin | Non-inferior complete resection rate |
Chemotherapy
References
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed NCT00003912
Cisplatin & Doxorubicin
| back to top |
PLADO: PLAtinol (Cisplatin) & DOxorubicin
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
|---|---|---|---|---|---|
| Ortega et al. 2000 | 1989-1992 | Phase 3 (E-switch-ic) | Cisplatin, 5-FU, Vincristine | More toxic | |
| Pritchard et al. 2000 (SIOPEL 1) | 1990-1994 | Non-randomized | |||
| Perilongo et al. 2009 (SIOPEL 3) | 1998-2006 | Phase 3 (C) | Cisplatin | Non-inferior complete resection rate |
Chemotherapy
References
- Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD; Children's Cancer Group; Pediatric Oncology Group. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. link to original article PubMed
- SIOPEL 1: Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000 Nov 15;18(22):3819-28. link to original article PubMed
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed NCT00003912
Cisplatin & Fluorouracil (CF) & Vincristine
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Katzenstein et al. 2019 (AHEP0731) | 2010-2014 | Phase 3 (E-esc) | Observation | Seems to have superior EFS |
For stage 1 or 2 hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology with complete resection at diagnosis and no history of prior chemotherapy or liver directed therapy. Eligible patients include: patients< 21 years old, elevated serum α-fetoprotein level (>100 ng/mL), at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status.
Preceding treatment
- Curative surgical resection
Chemotherapy
- Cisplatin as follows:
- Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
- 10 kg or more: 100 mg/m2 over 6 hours once on day 1
- Fluorouracil as follows:
- Less than 10 kg: 20 mg/kg IV once on day 2
- 10 kg or more: 600 mg/m2 IV once on day 2
- Vincristine as follows:
- Less than 10 kg: 0.05 mg/kg IV once per day on days 2, 9, 16
- 10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 2, 9, 16
21-day cycle for 1 cycle (to be given within 42 days of resection)
References
- AHEP0731: Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncology. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. link to original article PubMed NCT00980460